Tenax Therapeutics (NASDAQ:TENX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tenax Therapeutics (NASDAQ:TENX) to a sell rating in a research note issued to investors on Saturday.

A number of other brokerages have also issued reports on TENX. Piper Sandler began coverage on Tenax Therapeutics in a research note on Monday, September 8th. They set an “overweight” rating and a $20.00 price target for the company. Guggenheim decreased their price target on Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

TENX opened at $7.50 on Friday. Tenax Therapeutics has a 12 month low of $4.30 and a 12 month high of $8.24. The stock has a market cap of $34.20 million, a P/E ratio of -8.15 and a beta of 1.58. The stock’s 50 day moving average price is $6.68 and its 200 day moving average price is $6.14.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Wednesday, August 13th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.23. Equities analysts anticipate that Tenax Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

An institutional investor recently raised its position in Tenax Therapeutics stock. ADAR1 Capital Management LLC lifted its stake in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) by 98.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,741 shares of the specialty pharmaceutical company’s stock after acquiring an additional 34,048 shares during the quarter. ADAR1 Capital Management LLC owned 1.66% of Tenax Therapeutics worth $450,000 at the end of the most recent reporting period. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.